{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:11:38Z","timestamp":1790719898059,"version":"4.1.0"},"reference-count":26,"publisher":"CMA Impact Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["cmajo"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.9778\/cmajo.20220039","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T08:35:23Z","timestamp":1686645323000},"page":"E494-E503","source":"Crossref","is-referenced-by-count":48,"title":["Prescribing patterns and factors associated with sodium\u2013glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease"],"prefix":"10.9778","volume":"11","author":[{"given":"Aya F.","family":"Ozaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis T.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiming","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare L.","family":"Atzema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese A.","family":"Stukel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob A.","family":"Udell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Naimark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian L.","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Jackevicius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"382","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"2023061305351711000_11.3.E494.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"2023061305351711000_11.3.E494.2"},{"key":"2023061305351711000_11.3.E494.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"2023061305351711000_11.3.E494.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.09.020"},{"key":"2023061305351711000_11.3.E494.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"2023061305351711000_11.3.E494.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"2023061305351711000_11.3.E494.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.06.032"},{"key":"2023061305351711000_11.3.E494.8","doi-asserted-by":"crossref","first-page":"e216139","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2023061305351711000_11.3.E494.9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021084"},{"key":"2023061305351711000_11.3.E494.10","doi-asserted-by":"crossref","first-page":"e186125","DOI":"10.1001\/jamanetworkopen.2018.6125","article-title":"Association of second-line antidiabetic medications with cardiovascular events among insured adults with type 2 diabetes","volume":"1","author":"O\u2019Brien","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2023061305351711000_11.3.E494.11","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.2.183"},{"key":"2023061305351711000_11.3.E494.12","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/eurheartj\/ehab765","article-title":"SGLT2 inhibitors: the statins of the 21st century","volume":"43","author":"Braunwald","year":"2022","journal-title":"Eur Heart J"},{"key":"2023061305351711000_11.3.E494.13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.114.001416"},{"key":"2023061305351711000_11.3.E494.14","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-018-3148-0"},{"key":"2023061305351711000_11.3.E494.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001224"},{"key":"2023061305351711000_11.3.E494.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30668-8"},{"key":"2023061305351711000_11.3.E494.17","doi-asserted-by":"publisher","DOI":"10.1081\/QEN-120001878"},{"key":"2023061305351711000_11.3.E494.18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ahj.2020.03.017","article-title":"Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits","volume":"224","author":"Gao","year":"2020","journal-title":"Am Heart J"},{"key":"2023061305351711000_11.3.E494.19","unstructured":"Rogers EM (2003) Diffusion of innovations (Free Press, New York), 5th ed."},{"key":"2023061305351711000_11.3.E494.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"2023061305351711000_11.3.E494.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038"},{"key":"2023061305351711000_11.3.E494.22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.121.053766","article-title":"Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the cardiology community","volume":"144","author":"Nelson","year":"2021","journal-title":"Circulation"},{"key":"2023061305351711000_11.3.E494.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.15.1864"},{"key":"2023061305351711000_11.3.E494.24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/XCE.0000000000000195","article-title":"Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications","volume":"9","author":"Gunawan","year":"2020","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"2023061305351711000_11.3.E494.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001238"},{"key":"2023061305351711000_11.3.E494.26","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.cardfail.2021.05.015","article-title":"National trends in the use of sacubitril\/valsartan","volume":"27","author":"Ozaki","year":"2021","journal-title":"J Card Fail"}],"container-title":["CMAJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.9778\/cmajo.20220039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T08:35:39Z","timestamp":1686645339000},"score":1,"resource":{"primary":{"URL":"http:\/\/cmajopen.ca\/lookup\/doi\/10.9778\/cmajo.20220039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,6,13]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.9778\/cmajo.20220039"],"URL":"https:\/\/doi.org\/10.9778\/cmajo.20220039","relation":{},"ISSN":["2291-0026"],"issn-type":[{"value":"2291-0026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}